XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)
Year: 2026
Type: article
Abstract: INTRODUCTION: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4-5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. AIM: To present new developments in neurodegeneration and progression, the prodromal phase and diagnosis, the clinical use of biomarkers and neuroimaging, as well as the current role of patient-reported outcomes and digital monitoring. Highlights on the risk of infections and comorbidities in MS are also summarized. Content and Conclusions: In active MS lesions, there is no correlation between the myeloid cell phenotype and remyelination, while memory astrocytes, regulated by the CLEC16A gene, are present in chronic active lesions. Gray matter atrophy is associated with disability and progression independent of relapses, whereas cervical spinal cord atrophy predicts the prognosis of progressive forms and may lead to earlier diagnosis. Healthcare resource utilization increases in the years preceding the first demyelinating event, and although prodromal symptoms are highly variable, they are useful in identifying risk factors for the disease. The new McDonald criteria will facilitate the diagnosis of MS in patients with a radiologically isolated syndrome. Glial fibrillary acidic protein complements neurofilaments, and both biomarkers could soon be standardized for use in clinical practice; paramagnetic rim lesions and slowly expanding lesions are promising imaging markers. In another area, patient-reported health outcomes are valuable, although they are subject to selection bias and the need to define boundaries for their use. Finally, the risk of infections increases before diagnosis and may worsen with certain treatments. Comorbidities in MS should be managed as an integral part of disease management.
Source: Revista de Neurología
DOI: 10.31083/rn39227
Authors: Óscar Fernández, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, Tamara Castillo-Triviño, Lucienne Costa-Frossard, Sara Eichau, Miguel Ángel Hernández, Lamberto Landete, Miguel Llaneza, Sara Llufriu, José E. Meca-Lallana, Virginia Meca-Lallana, Ester Moral, Celia Oreja-Guevara, José María Prieto, Lucía Romero-Pinel, Andreu Vilaseca, Alfredo Rodríguez-Antigüedad
Institutions: Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Complejo Asistencial Universitario de León, Hospital Universitario Reina Sofía, Hospital Universitario de Getafe, Hospital Universitario Quirónsalud Madrid, IDCQ Hospitales y Sanidad, S.L.U., Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Hospital Universitario Son Espases, Biogipuzkoa Health Research Institute, Donostiako Unibertsitate Ospitalea, Hospital Universitario Ramón y Cajal, Hospital Universitario Virgen Macarena, Hospital Universitario Nuestra Señora de Candelaria, Hospital Universitario Doctor Peset, Hospital Universitario Central de Asturias, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Universidad Católica de Murcia, Hospital Universitario de La Princesa, Hospital de Sant Joan Despí Moisès Broggi, Universidad Complutense de Madrid, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Instituto de Investigación Sanitaria de Santiago, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, Hospital de Cruces
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Merck
OpenAlex ID: W7126034652